Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its CMAB015, a biosimilar of Novartis’ Cosentyx (secukinumab). The study will target psoriasis and ankylosing spondylitis.
Drug Profile
Cosentyx was first approved in China in March 2019 for moderate to severe plaque psoriasis and received approval for ankylosing spondylitis in 2020. The drug was included in the National Reimbursement Drug List (NRDL) the same year.
Competitive Landscape
Similar products on the market include:
- Taltz (ixekizumab): Eli Lilly’s product already on the market.
- SHR-1314: Hengrui Medicine’s biosimilar.
- GR1501: Zhixiang Jintai Bio’s biosimilar.
- BAT2306: Bio-Thera’s biosimilar.
- QX002N: Qyuns Bio’s biosimilar.
- JS005: Junshi Bio’s biosimilar.
- HB0017: Huahai Pharma’s biosimilar.
- IL-17A mAb: Sunshine Guojian’s product.
- IL-17A/F mAb: Livzon Group’s product.-Fineline Info & Tech
